DISCUSSION PAPER SERIES

DP15974

Dementia and Disadvantage in the United States and England

Eric Baird French, Jeremy McCauley, Eric Brunner and Karolos Arapakis

PUBLIC ECONOMICS



Dementia and Disadvantage in the United States and England

Eric Baird French, Jeremy McCauley, Eric Brunner and Karolos Arapakis

Discussion Paper DP15974 Published 27 March 2021 Submitted 26 March 2021

Centre for Economic Policy Research 33 Great Sutton Street, London EC1V 0DX, UK Tel: +44 (0)20 7183 8801 www.cepr.org

This Discussion Paper is issued under the auspices of the Centre's research programmes:

• Public Economics

Any opinions expressed here are those of the author(s) and not those of the Centre for Economic Policy Research. Research disseminated by CEPR may include views on policy, but the Centre itself takes no institutional policy positions.

The Centre for Economic Policy Research was established in 1983 as an educational charity, to promote independent analysis and public discussion of open economies and the relations among them. It is pluralist and non-partisan, bringing economic research to bear on the analysis of medium- and long-run policy questions.

These Discussion Papers often represent preliminary or incomplete work, circulated to encourage discussion and comment. Citation and use of such a paper should take account of its provisional character.

Copyright: Eric Baird French, Jeremy McCauley, Eric Brunner and Karolos Arapakis

Dementia and Disadvantage in the United States and England

Abstract

We compare dementia prevalence and how it varies by socioeconomic status (SES) across the United States and England. We compare between country differences in age-gender standardized dementia prevalence, across the SES gradient. Dementia prevalence was estimated in each country using an algorithm based on an identical battery of demographic, cognitive, and functional measures. Dementia prevalence is higher among the disadvantaged in both countries, with the United States being more unequal according to four measures of SES. Once past health factors and education were controlled for, most of the within country inequalities disappeared; however, the cross-country difference in prevalence for those in lowest income decile remained disproportionately high. This provides evidence that disadvantage in the United States is a disproportionately high risk factor for dementia.

JEL Classification: I14, I32

Keywords: dementia, disadvantage, socioeconomic gradient

Eric Baird French - eric.french.econ@gmail.com University of Cambridge and CEPR

Jeremy McCauley - jeremymccauley@gmail.com University of Bristol

Eric Brunner - e.brunner@ucl.ac.uk university college london

Karolos Arapakis - karolos.arapakis.14@ucl.ac.uk university college london

Acknowledgements

We thank Paco Martorell and Ken Langa for help with understanding the prediction equations and Liliana French for editorial assistance. This work was supported by grants from the British Heart Foundation (RG/13/2/30098, RG/16/11/32334), MRRC, ESRC, and Onassis Foundation.

Dementia and Disadvantage in the United States and England:

Population-based comparative study

By Karolos Arapakis, Eric J Brunner, Eric French, Jeremy McCauley^{*}

Objectives – To compare dementia prevalence and how it varies by socioeconomic status (SES) across the United States and England.

Design – Population-based comparative study.

Setting - Non-Hispanic whites aged over 70 population in the United States and England.

Participants – Data from the Health and Retirement Study (HRS) and the English Longitudinal Study of Ageing (ELSA), which are harmonised, nationally representative panel studies. The sample includes 5,330 and 3,147 individuals in the United States and England, respectively.

Main outcome measures – Between country differences in age-gender standardized dementia prevalence, across the SES gradient. Dementia prevalence was estimated in each country using an algorithm based on an identical battery of demographic, cognitive, and functional measures.

Results – Dementia prevalence is higher among the disadvantaged in both countries, with the United States being more unequal according to four measures of SES. Overall prevalence was lower in England at 9.7% (95% CI, 8.9% to 10.6%) than the US at 11.2% (95% CI, 10.6% to 11.8%), a difference of 1.4 percentage points (pp) (p = 0.0055). Most of the between country difference is driven by the bottom of the SES distribution. In the lowest income decile individuals in the US had 7.3 pp (p < 0.0001) higher prevalence than in England. Once past health factors and education were controlled for, most of the within country inequalities disappeared; however, the cross-country difference in prevalence for those in lowest income decile remained disproportionately high.

Conclusions – There is inequality in dementia prevalence according to income, wealth, and education in both the US and England. England has lower dementia prevalence and a less steep SES gradient. Most of the cross-country difference is concentrated in the lowest SES group, which provides evidence that disadvantage in the United States is a disproportionately high risk factor for dementia.

^{*} Department of Economics, University College London, London, UK (K Arapakis MSc, Prof E French PhD)

Department of Epidemiology and Public Health, University College London, London, UK (Prof E J Brunner PhD)

Department of Economics, University of Bristol, Bristol, UK (J McCauley PhD)

Institute for Fiscal Studies, London, UK (E French) Correspondence to: Jeremy McCauley, School of Economics, University of Bristol, Bristol BS8 1TU, UK jeremy.mccauley@bristol.ac.uk

Strengths and limitations of this study

- This is the first study to compare dementia prevalence across countries using the same survey
 methodology and the exact same measure of dementia. The surveys have similar sample selection
 and questionnaire design. We standardise our estimates by age and gender to the English
 population aged over 70 in 2016. Any differences in overall prevalence across the two countries
 should represent true differences.
- We measure the SES gradient of dementia across four different measures of SES: income; education; wealth; and non-housing wealth.
- Dementia disproportionately affects the most disadvantaged in in both countries, although the gradient is steeper in the US according to all four measures of SES.
- We do not ascertain dementia directly, but predict cases using a common battery of measures in ELSA and HRS. One of the SES measures, education, is also used as a predictor of dementia.

Introduction

Dementia, a severe and irreversible decline in memory and other cognitive functions, is a major and increasing global health challenge. It is the fifth leading cause of death globally and is one of the most common comorbidities for Covid-19 morbidity.[1,2] It results in large social and economic costs.[3,4] Americans are more likely to be in poor health than their English counterparts in multiple dimensions, including heart disease and diabetes.[5] These differences are large along all points of the socioeconomic status (SES) gradient, although the gradient is generally steeper in the US. While the SES gradient for many diseases has been well established, [6-8] only a few studies have focused specifically on dementia.[9,10] The available evidence is summarized in Table A1 in the online appendix. The evidence of the SES gradient for dementia is also less clear, as in England while a strong association has been established between wealth and dementia incidence, the same was not observed for education level.[11] The Global Burden of Disease Study (GBD) reported that in 2017 among those aged over 70, the US had a lower overall prevalence of dementia at 7.89% compared with the UK at 8.91%.[12] However, the GBD has identified substantial heterogeneity in case-ascertainment methods throughout the dementia literature. resulting in location-specific inconsistencies and potentially biased cross-country comparisons. This has led to calls for analyses with more consistent and comparable measures of dementia to inform policy makers, researchers, and clinicians about global differences in dementia.[13]

In this study, we compared dementia prevalence in England and the US among non-Hispanic whites aged 70+, and how it varied across the SES gradient of each country. Location-specific inconsistencies caused by differences in diagnostic practices were not an issue in our study because we used an identical case definition for dementia, and the surveys in the analysis shared the same design and sampling techniques. More specifically, we used two large surveys, the US Health and Retirement Study (HRS) and the English Longitudinal Study of Ageing (ELSA), that contain a battery of the same demographic, cognitive, and functional measures, and we applied the same prediction algorithm in both countries to detect undiagnosed as well as diagnosed cases. We compared dementia prevalence within and across England and the US using important indicators of SES, specifically: income; education; wealth; and non-housing wealth.

Methods

Description of Surveys

Data were extracted from the 2016 and earlier waves of the HRS and ELSA, which are nationally representative biennial surveys of the US and English populations, respectively.[14,15] Both the HRS and ELSA follow respondents longitudinally until death, with new cohorts entering to maintain population representativeness as the study sample gets older. The design of ELSA was based on the HRS, making the two surveys analogous, with both collecting data on health, ability, demographics, employment, and wealth. In addition to measuring health conditions and difficulties respondents have with Activities of Daily Living (ADLs) and Instrumental Activities of Daily Living (IADLs), sample members also have their cognitive function assessed. A range of tests adapted from the Telephone Interview for Cognitive Status (TICS) have been carried out in HRS since 1996 and ELSA since 2014. If a sample member was unable to respond in person, a proxy respondent was asked questions about the respondent's change in memory. Both surveys

have a high response rate, which is displayed in the online appendix Table A2. We describe these surveys in more detail in the online appendix.

Cohort Description

Our samples are restricted to non-Hispanic whites over the age of 70 years old that live in the community or in nursing homes in 2016. This provides a study sample of 5,330 participants in the HRS and 3,147 participants in ELSA. We restrict our sample to non-Hispanic whites to ensure estimates are comparable across countries. Summary statistics of both the raw and selected samples are displayed in online appendix Tables A3 and A4, and specifications that include ethnic minorities are also displayed.

Patient and Public Involvement

No study participants were involved in setting the research question or outcome measures, nor were they involved in any other area of the design, implementation, and analysis of the study. There are no direct plans to disseminate the results of the research to study participants.

Dementia Case Definition

The HRS included a detailed clinical substudy (ADAMS: Aging, Demographics and Memory Study) of 856 sample members aged 70+ who completed an in-depth in-home assessment of cognitive status conducted by experienced teams at the Duke University Dementia Epidemiology Research Center who diagnosed each participant as normal, cognitively impaired but not demented (CIND), or demented.[3] Data from ADAMS is regarded as the gold-standard dementia diagnoses against which to train algorithms to predict dementia.[16] Hurd et al. estimated separate ordered probit models in the ADAMS subsample for self- and proxy-respondents to generate a predictive algorithm for cognitive status, based on the ADAMS diagnoses, for the whole HRS sample. The algorithm uses a range of variables including demographic information, Activities of Daily Living (ADLs), Instrumental Activities of Daily Living (IADLs), TICS questionnaire, as well as the change in these variables across waves.[3] Proxy respondents had a separate predictive algorithm as they were asked a different set of questions from self-respondents, which included the short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE). The use of a proxy to assess cognitive decline and dementia in elderly people is a recognised accepted standard method for identifying severe cognitive impairment and has been validated many times.[17] Importantly, the same set of questions used in the Hurd et al. algorithm is asked of self- and proxy-respondents in both HRS and ELSA. Summary statistics for a variety of predictors are displayed in online appendix Table A5.

We applied Hurd et al.'s predictive algorithm to estimate the probably of dementia for those in the HRS sample in 2016 and extended the prediction to the ELSA sample. The algorithm predicts the probability of dementia in the following year; therefore, we predicted dementia prevalence in 2017. Hurd et al's predictive algorithm has been shown to have an accuracy (percentage correctly classified as demented or non-demented) of 94%, sensitivity of 65%, and a specificity of 98% in the estimation sample.[16] An in-depth discussion of the predictive algorithm procedure can be found in the online appendix.

Non-response for people unable or unwilling to participate in the survey is important when attempting to estimate dementia prevalence across the population. While attrition exists in both surveys, it is unlikely to significantly affect our estimates since among older ELSA and HRS respondents there is no statistically significant correlation between attrition and prior health or the SES indicators of education, income and wealth.[18]

Measures of Socioeconomic Status

We considered four measures of SES: income; education; wealth; and non-housing wealth. Income is measured as current household income from all sources. For education we used total years of schooling. "Wealth is measured as the sum of all household reported savings, stocks, bonds, business wealth, other assets, and the value of housing assets (e.g., properties) after financial debt and mortgage debt has been subtracted. Non-housing wealth is the same measure as wealth but excludes housing assets and mortgage debt, and therefore measure wealth that can be more easily converted to cash. Wealth and non-housing wealth are both measured from 4 years prior to minimize reverse causality, as medical expenses associated with dementia are high and may run down wealth.[4] For each measure, we created a SES gradient by ranking individuals based on that measure. For income, wealth, and non-housing wealth, we assigned everyone to a decile in their respective country. For education, we ranked individuals according to their number of years of schooling.

Statistical Analysis

We created a pooled dataset of the two surveys. In our statistical analysis we used HRS and ELSA sampling weights to adjust for nonresponse and for the sampling design of the surveys. To make both within country estimates along the SES gradient and cross-country estimates directly comparable, estimates were agegender standardized to the English population aged over 70 in 2016 using direct standardization, categorising the population into ten groups: five age bands (70-74; 75-79; 80-84; 85-89; and 90+) by gender. We estimated the prevalence of dementia in each country, their difference, and compared the prevalence along the four SES gradients. For each estimate presented we computed the corresponding 95% confidence interval (CI), and for any differences we computed the corresponding p-values. For each SES factor, as well as estimating the age-gender standardized prevalence along the gradient, we calculated the Relative Index of Inequality (RII) and Slope Index of Inequality (SII) using generalized linear models (log binomial regression) with logarithmic and identity link functions, respectively. The RII can be interpreted as the relative likelihood of dementia prevalence of those in the lowest SES group compared to those in the highest, and the SII can be interpreted as the absolute effect on dementia probability of moving from the lowest SES group to the highest.[19] To assess whether any observed differences could be explained by disparities in past health risk factors across countries we conditioned on a variety of risk factors and assessed how our estimates changed. Where possible, when conditioning on these factors we used past health instead of current health to address the problem of reverse causality: i.e., the problem that dementia may cause health problems such as low weight. Statistical analyses were performed using STATA software.

Results

Table 1 shows the age-gender standardized prevalence of dementia for the aged over 70 white non-Hispanic population in both England and the US. Dementia prevalence is lower in England at 9.7% (95% CI, 8.9% to 10.6%) than the US at 11.2% (95% CI, 10.6% to 11.8), a difference of 1.4 percentage points (pp) that is highly statistically significant (P = 0.0055).

Table 1 also shows dementia prevalence for different SES groups, in terms of income, education, wealth, and non-housing wealth. Regardless of the measure of the SES, there is a clear gradient in dementia prevalence, with the most disadvantaged groups in both England and the US having higher dementia prevalence. The gradient is steeper in the US and is driven by significantly higher dementia prevalence for those at the very bottom of the distribution. In the US, those in the lowest income decile have a dementia prevalence of 18.7% (95% CI, 16.6% to 20.8%), which is considerably higher than in England, with a prevalence among those in the lowest decile of 11.4% (95% CI, 8.9% to 13.9%). The difference is highly statistically significant (P < 0.0001). For income deciles above the lowest, the difference across the two countries is much smaller and not statistically significant. This same general pattern is evident across the other measures of SES that we consider, although when using wealth, the difference between those in the bottom decile is not statistically significant.

Figure 1 presents the same dementia prevalence information shown in Table 1, but in graphical format. It also reports the Slope Index of Inequality (SII) for the four different measures of the SES for both countries. In both the US and England, dementia is more prevalent among the more disadvantaged. The gradient tends to be steeper in the US, corresponding to a larger (in absolute value) SII in the US for each SES measure. For income, the SII is -0.062 (95% CI, -0.097 to -0.028) and -0.085 (95% CI, -0.114 to -0.057) for England and the US, respectively. The SIIs are not statistically different. If the lowest income decile is excluded, the SII for England becomes slightly steeper (-0.067 (95% CI, -0.107 to -0.027)) whereas the SII for the US becomes less steep than England (-0.060 (95% CI, -0.093 to -0.027)).

Next, we attempted to understand the potential drivers of these gradients and the differences in the gradients across countries. We extended the analysis to account for cardiometabolic diseases (i.e. diabetes, heart disease and stroke), and behaviours (i.e. smoking and body mass index) as dementia risk factors.[1,20] Previous research showed these factors to be more prevalent in the US than England, especially among the most disadvantaged.[5] Table 2 displays the percentage point difference in dementia prevalence after we controlled for various measures of past health and behaviours. The results are split into three panels: the whole sample; the whole sample excluding those in the lowest income decile; and the lowest income decile. As was shown in Table 1, the difference in the prevalence of dementia between England and the US was 1.43 pp (P = 0.0055). Table 2 shows this difference declined to 0.894 pp (P = 0.11) when we excluded the lowest income decile. Controlling for past health and behaviours modestly reduced this cross-country difference further: the difference declined by a maximum of 19%. For the lowest income decile, controlling for past health and behaviour reduced the cross-country difference of 7.27 pp (P < 0.0001) by a more substantial 33%.

In the online appendix Tables A6-A8 we investigated whether past health and behaviour explained the SES gradient within each country. We found that in England and the US these factors accounted for most of

the SES gradient, as shown in online appendix Figure A1. However, in the US, prevalence in the lowest income decile remained disproportionately high.

Education has also been shown to be a risk factor for dementia. Table 1 shows that in both the US and England, the less educated have higher dementia prevalence. Controlling for education increased the estimated difference across countries, from 1.43 pp to 2.82 pp, as can be seen in the online appendix Table A7. Education cannot explain these differences since the English have lower educational attainment.

In our main analysis we exclude ethnic minorities, who have higher dementia prevalence and comprise a larger share of the US than the English population. Including minorities increased the estimated difference across countries, from 1.43 pp to 2.42 pp, as can be seen in the online appendix Tables A9 and A10. This is largely caused by the high prevalence of dementia among minorities in the US as displayed in online appendix Table A11.

Discussion

Main findings

Using nationally representative samples of older individuals from England and the US, and applying the same algorithmic procedure to predict dementia in both samples, we showed that in both the US and England dementia is more prevalent among the disadvantaged, and the SES gradient of dementia is steeper in the US. The steeper gradient in the US is largely driven by those in the lowest decile. In both countries, most of the SES gradient disappeared when we controlled for past health related factors, although prevalence for those in lowest income decile in the US remained disproportionately high. If the lowest income decile is excluded from our sample the difference in dementia prevalence across the countries is statistically insignificant, and the remaining SES gradient of dementia is remarkably similar across countries.

While poorer individuals face a higher burden of dementia in both England and the US, the extremely poor in the US face a disproportionately high burden of dementia. Controlling for past health-related factors can explain some, but not all, of the cross-country difference. It can explain up to around one third of the difference for those in the lowest income decile. While past health factors such as adiposity and smoking are correlated with dementia, those in the lowest income decile in the US do not smoke more or have higher BMIs than their English counterparts. Therefore, this cannot explain their disproportionately higher prevalence of dementia. Education also cannot explain the difference, as the US population is more educated at every income decile, and in fact the educational difference masks some of the underlying dementia risk difference between countries.

Adding minorities increased estimated dementia prevalence, especially in the US, because dementia prevalence is higher among minorities, who comprise a higher share of the US than the English population. This fits with prior research which showed dementia prevalence is higher for non-whites and Hispanics.[20,21] We did not observe higher dementia prevalence among Hispanics and non-whites in the US for those in relatively high socioeconomic groups.

Comparison with previous studies and how findings are an advance on current literature

Previous studies have shown cross-country variation in dementia prevalence. However, substantial heterogeneity in case-ascertainment methods across countries and studies makes interpreting any observed differences difficult. We believe this is the first study to compare dementia prevalence in England and the US using the exact same measure of dementia, thus overcoming previous difficulties in making comparisons across the two countries due differences in diagnostic practices and case definitions. We also compared the SES gradient of dementia in both countries. While some studies have shown in both England and the US those with lower education and less wealth have been found to have higher rates of dementia,[4,9,11,22,23] there are no systematic comparative studies. We compared prevalence along the SES gradient using almost identical measures of income, wealth, and education. Further, we standardized the cross-country comparison for age and gender, using the English over 70 population as the standard population. We found that dementia prevalence is higher and more concentrated among the poorest in the US than England. Detailed disaggregation according to SES measures shows the true extent of the excess burden of dementia in the very poorest group in the US.

We showed that risk factors for dementia such as cardiometabolic diseases, psychiatric conditions, high BMI, smoking have similar affects across countries. Accounting for these risk factors removes most of the SES gradient for both countries, but disproportionately high prevalence remains for the most disadvantaged in the US.

Implications (wider interpretation)

Much research has shown that low income Americans are more likely to be in poor health and die younger than their high-income counterparts.[24] We show that these health differences also extend to dementia prevalence.

While risk factors contribute to higher prevalence among those who are more disadvantaged, those in the US appear to have an undue burden that is caused by risk factors for which we cannot account. One possible explanation is differential access to healthcare. The NHS provides broadly equitable care according to education in the older population after accounting for health status.[25] In the US, the poor often go uninsured, and although virtually every American aged 65 or older is eligible for Medicare, around 20% of Medicare beneficiaries healthcare must be financed out of pocket.[26] The extent to which health care provision below and above aged 65 may account for the relative excess dementia burden in the US is unclear.

The implications of our results are that interventions designed to attempt to prevent dementia should be targeted towards the most disadvantaged. This is especially true in the US. As yet, we are unable to advocate specific measures as we do not yet understand the specific nature of disadvantage in respect to dementia risk.

Strengths and Weaknesses of Analysis

This study has a strong design. Results are directly comparable across England and the US. The same predictive algorithm was applied to both countries, addressing the problem of heterogeneity in case ascertainment which has affected the literature.[1,13] Further, because ELSA and HRS share sample

selection and questionnaire design, any differences in overall prevalence and SES gradients in prevalence across the two countries should represent true differences. In contrast to the Global Burden Disease study, we find higher dementia prevalence in the US. Furthermore, we measured the SES gradient of dementia across four different measures of SES, with consistent results. Our work also highlights the usefulness of the standardized measure of dementia to allow for meaningful comparisons across countries.

This study had three limitations. First, we do not ascertain dementia directly, but predict cases using a common battery of measures in ELSA and HRS. Importantly, Hurd's prediction algorithm has high accuracy and although our case definition lacks a clinical point of reference in England, it is based on a detailed clinical substudy in the US.[16] Further, cross-cultural subjectivities in reporting of impairment severity are likely to be similar in the US and England (see online appendix Table A5). It would be of great value for future work to use the Harmonized Cognitive Assessment Protocol (HCAP) data to provide a standard clinical point of reference to validate and verify the cross-country dementia prevalence estimates.[27] Second, education is one of the factors in the predictive algorithm for dementia and also one of our measures of SES. The dementia algorithm takes account of the well-documented correlation between education level and cognitive function in adult life. Nevertheless, we found substantial absolute and relative inequalities in dementia prevalence according to education level in the US and UK. Education may be a successful approach for reducing dementia risk.[28] Third, while we show risk factors explain a large proportion of the differences in dementia between the England and the US – although cannot account for the difference in the lowest income decile – there are likely other unmeasured confounding factors that impact dementia prevalence which we do not observe.

Conclusion

Given the large social and economic costs of dementia, there is great value in understanding the scope and burden of dementia in the population along the SES gradient. This study indicates that more disadvantaged individuals face a higher burden of dementia and that the poorest individuals in the US face a disproportionately high burden. The high burden faced by these individuals can be partly but not fully explained by past health factors. We lacked data on other important possible contributing factors such as habitual drug use. Further research is needed to fully understand this issue using data from multiple sources.

	England Age-Gender Standardized Prevalence [95% CI]		United States Age-Gender Standardized		Difference	p-value
-						
-			Prev	alence [95% Cl]		
All	0.007	[0 089 to 0 106]	0 112	[0 106 to 0 118]	0.014	0 0055
Household Income D		[0.009 to 0.100]	0.112	[0.100 10 0.110]	0.014	0.0000
1 (Lowest)	0.114	[0.089 to 0.139]	0.187	[0.166 to 0.208]	0.073	<0.0001
2	0.113	[0.090 to 0.136]	0.141	[0.119 to 0.163]	0.028	0.090
3	0.124	[0.097 to 0.151]	0.111	[0.095 to 0.127]	-0.013	0.42
4	0.099	[0.071 to 0.126]	0.118	[0.099 to 0.137]	0.019	0.26
5	0.094	[0.072 to 0.116]	0.086	[0.069 to 0.102]	-0.008	0.56
6	0.098	[0.070 to 0.127]	0.108	[0.088 to 0.128]	0.010	0.59
7	0.068	[0.042 to 0.093]	0.100	[0.078 to 0.122]	0.032	0.060
8	0.083	[0.053 to 0.114]	0.082	[0.066 to 0.097]	-0.002	0.92
9	0.082	[0.041 to 0.122]	0.093	[0.071 to 0.116]	0.012	0.62
10 (Highest)	0.059	[0.035 to 0.083]	0.077	[0.052 to 0.103]	0.019	0.30
Years of Schooling	0.000		0.011		0.0.0	0.00
9 or fewer	0.128	[0.101 to 0.154]	0.190	[0.162 to 0.218]	0.062	0.0015
10	0.095	[0.074 to 0.116]	0.137	[0.109 to 0.165]	0.042	0.018
11	0.096	[0.077 to 0.115]	0.109	[0.080 to 0.139]	0.013	0.471
12	0.071	[0.042 to 0.100]	0.124	[0.114 to 0.133]	0.053	0.0006
13	0.061	[0.038 to 0.083]	0.116	[0.090 to 0.141]	0.055	0.0013
14 or more	0.056	[0.039 to 0.073]	0.085	[0.076 to 0.093]	0.029	0.0031
Household Wealth De	ecile					
1 (Lowest)	0.165	[0.132 to 0.198]	0.187	[0.162 to 0.211]	0.022	0.31
2	0.117	[0.092 to 0.143]	0.149	[0.129 to 0.169]	0.031	0.061
3	0.100	[0.073 to 0.127]	0.107	[0.091 to 0.122]	0.006	0.68
4	0.093	[0.071 to 0.115]	0.115	[0.098 to 0.132]	0.022	0.12
5	0.110	[0.085 to 0.134]	0.091	[0.077 to 0.106]	-0.018	0.21
6	0.080	[0.057 to 0.103]	0.089	[0.074 to 0.103]	0.008	0.55
7	0.070	[0.046 to 0.094]	0.103	[0.084 to 0.123]	0.034	0.034
8	0.092	[0.066 to 0.118]	0.089	[0.072 to 0.106]	-0.003	0.85
9	0.082	[0.048 to 0.116]	0.103	[0.084 to 0.123]	0.021	0.28
10 (Highest)	0.060	[0.038 to 0.081]	0.067	[0.051 to 0.084]	0.008	0.58
Household Non-Hous	ing Wealth	n Decile				
1 (Lowest)	0.136	[0.103 to 0.168]	0.201	[0.176 to 0.226]	0.065	0.0019
2	0.109	[0.084 to 0.134]	0.137	[0.119 to 0.156]	0.029	0.074
3	0.123	[0.095 to 0.151]	0.131	[0.111 to 0.150]	0.008	0.66
4	0.096	[0.073 to 0.118]	0.101	[0.085 to 0.116]	0.005	0.71
5	0.108	[0.082 to 0.134]	0.107	[0.091 to 0.123]	-0.001	0.95
6	0.093	[0.067 to 0.119]	0.086	[0.070 to 0.101]	-0.007	0.64
7	0.099	[0.072 to 0.125]	0.086	[0.070 to 0.102]	-0.013	0.42
8	0.078	[0.051 to 0.105]	0.090	[0.073 to 0.106]	0.011	0.49
9	0.058	[0.036 to 0.081]	0.092	[0.074 to 0.111]	0.034	0.024
10 (Highest)	0.063	[0.043 to 0.084]	0.079	[0.062 to 0.095]	0.015	0.26

Table 1: Prevalence of Dementia, United States vs. England, 2017. Overall prevalence and prevalence according to four measures of socioeconomic status

Notes: Sample includes non-Hispanic white population aged 70+ only. The sample size is 3,147 participants in England and 5,330 participants in the United States. All estimates are age-gender standardized to the overall 2016 aged 70+ white population in England. The difference is calculated as the prevalence in the US minus prevalence in England. All deciles are calculated within country.

Figure 1: SES Gradient of Dementia, United States vs England, 2017, according to four measures of socioeconomic status. Absolute and relative inequality shown with 95% confidence intervals.

[Figure 1 Attached separately]

Notes: The points in this figure represent the mean age-gender standardized dementia prevalence for each country by socioeconomic status (SES), along with 95% confidence interval for these predictions. The solid lines represent the fitted Slope Index of Inequality (SII: absolute inequality) for each country. The values of the SII and the corresponding Relative Index of Inequality (RII: relative inequality) are listed in the top right of each figure, with 95% Confidence Intervals in brackets. For education, individuals are ranked based on their years of schooling within each country, and as the US has higher educational attainment, individuals with 14+ years of schooling are the 80th percentile of the US education distribution, but at the 90th percentile of the English educational distribution.

Table 2: Difference in Prevalence of Dementia, United States vs England, 2017. Estimates of the between-country difference taking account of antecedent health status, smoking and degree of adiposity

Whole Sample: Percentage Point Difference <i>p-value</i> % Difference from Baseline	1.43 0.0055 	1.34 0.0091 -6%	1.15 0.025 -19%	1.21 0.020 -16%	1.18 0.034 -17%
Excluding Lowest Income Decile:					
Percentage Point Difference	0.89	0.88	0.74	0.75	0.81
p-value	0.11	0.11	0.18	0.18	0.18
% Difference from Baseline		-2%	-17%	-16%	-10%
Lowest Income Decile:					
Percentage Point Difference	7.27	6.14	5.45	5.93	4.85
p-value	<0.0001	0.0003	0.002	0.0011	0.012
% Difference from Baseline		-15%	-25%	-18%	-33%
Control for:					
Past Cardiometabolic Diseases		\checkmark	\checkmark	\checkmark	\checkmark
Past Psychiatric Conditions			\checkmark	\checkmark	\checkmark
Ever Smoked				\checkmark	\checkmark
Past BMI					\checkmark

Notes: Sample includes non-Hispanic white population aged 70+ only. The sample size is 3,147 participants in England and 5,330 participants in the United States. All estimates are age-gender standardized to the overall 2016 aged 70+ white population in England. The difference is calculated as the prevalence in the US minus prevalence in England. Differences are displayed as percentage points. 'Past Cardiometabolic Diseases' and 'Past Psychiatric Conditions' control for whether an individual says they had the conditions 4 years prior. 'Cardiometabolic Diseases' include diabetes, heart disease, and stroke. 'Smoking' controls for whether an individual has ever smoked. BMI stands for Body Mass Index. 'Past BMI' includes dummy variables to control for whether an individual is classed as underweight, overweight, or obese. BMI values are based on when an individual first entered the survey, which is at least 10 years prior.

Contributors and Transparency Statement

All authors made a substantial contribution to study conception and design. EF and JM developed the original idea. JM and KA prepared and analysed the data, with inputs from EF and EJB. All authors contributed to interpreting the results and drafting the manuscript. JM and KA serve as guarantors and affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained. All authors had full access to all of the data (including statistical reports and tables) in the study and take responsibility for the integrity of the data and accuracy of the data analysis. The corresponding author (JM) attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. Author names on manuscript are listed in alphabetical order.

Competing interests

All authors have completed the ICMJE uniform disclosure form and declare no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work

Acknowledgments

We thank Paco Martorell and Ken Langa for help with understanding the prediction equations and Liliana French for editorial assistance.

Ethical approval

The HRS has ethical approval from the University of Michigan Institutional Review Board. ELSA has ethical approval from the London Multicentre Research Ethics Committee (MREC/01/2/91). This study did not require additional ethical approval as we conduct secondary analysis of these two publicly available datasets.

Funding

This work was supported by grants from the British Heart Foundation (RG/13/2/30098, RG/16/11/32334), MRRC, ESRC, and Onassis Foundation.

Data sharing

Appendix with details on the formula and calculations is available online. Code and results are available on request from the corresponding author.

References

- 1 Nichols E, Szoeke CE, Vollset SE, *et al.* Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol* 2019;**18**:88–106.
- 2 Kuo C-L, Pilling LC, Atkins JL, *et al.* ApoE e4e4 genotype and mortality with COVID-19 in UK Biobank. *medRxiv* 2020.
- 3 Hurd MD, Martorell P, Delavande A, *et al.* Monetary costs of dementia in the United States. *N Engl J Med* 2013;**368**:1326–34.
- 4 Hudomiet P, Hurd MD, Rohwedder S. The relationship between lifetime out-of-pocket medical expenditures, dementia, and socioeconomic status in the US. *J Econ Ageing* 2019;**14**:100181.
- 5 Banks J, Marmot M, Oldfield Z, *et al.* Disease and disadvantage in the United States and in England. *Jama* 2006;**295**:2037–45.
- 6 Marmot MG. Status syndrome: a challenge to medicine. Jama 2006;295:1304-7.
- 7 Brunner EJ. Social factors and cardiovascular morbidity. *Neurosci Biobehav Rev* 2017;74:260–8.
- 8 Marmot M. Health equity in England: the Marmot review 10 years on. *Bmj* 2020;**368**.
- 9 Rusmaully J, Dugravot A, Moatti J-P, et al. Contribution of cognitive performance and cognitive decline to associations between socioeconomic factors and dementia: A cohort study. PLoS Med 2017;14:e1002334.
- 10 George KM, Lutsey PL, Kucharska-Newton A, *et al.* Life Course Individual and Neighborhood Socioeconomic Status and Risk of Dementia in the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). *Am J Epidemiol* 2020.
- 11 Cadar D, Lassale C, Davies H, *et al.* Individual and area-based socioeconomic factors associated with dementia incidence in England: evidence from a 12-year follow-up in the English longitudinal study of ageing. *JAMA Psychiatry* 2018;**75**:723–32.
- 12 Global Burden of Disease. Global Burden of Disease. GBD Compare. IHME Viz Hub. GBD Comp. Viz Hub. https://vizhub.healthdata.org/gbd-compare/ (accessed 18 Jul 2020).
- 13 Launer LJ. Statistics on the burden of dementia: need for stronger data. Lancet Neurol 2019;18:25-7.
- 14 Sonnega A, Faul JD, Ofstedal MB, *et al.* Cohort profile: the health and retirement study (HRS). *Int J Epidemiol* 2014;**43**:576–85.
- 15 Steptoe A, Breeze E, Banks J, *et al.* Cohort profile: the English longitudinal study of ageing. *Int J Epidemiol* 2013;**42**:1640–8.
- 16 Gianattasio KZ, Wu Q, Glymour MM, *et al.* Comparison of methods for algorithmic classification of dementia status in the health and retirement study. *Epidemiol Camb Mass* 2019;**30**:291.
- 17 Jorm AF, Christensen H, Korten A, *et al.* Informant ratings of cognitive decline in old age: validation against change on cognitive tests over 7 to 8 years. *Psychol Med* 2000;**30**:981–5.
- 18 Banks J, Muriel A, Smith JP. Attrition and health in ageing studies: evidence from ELSA and HRS. *Longitud Life Course Stud* 2011;**2**:101–26.
- 19 Wagstaff A, Paci P, Van Doorslaer E. On the measurement of inequalities in health. *Soc Sci Med* 1991;**33**:545–57.

- 20 Yaffe K, Falvey C, Harris TB, et al. Effect of socioeconomic disparities on incidence of dementia among biracial older adults: prospective study. *Bmj* 2013;**347**.
- 21 Vega IE, Cabrera LY, Wygant CM, *et al.* Alzheimer's disease in the latino community: Intersection of genetics and social determinants of health. *J Alzheimers Dis* 2017;**58**:979–92.
- 22 Langa KM, Larson EB, Crimmins EM, *et al.* A comparison of the prevalence of dementia in the United States in 2000 and 2012. *JAMA Intern Med* 2017;**177**:51–8.
- 23 Rocca WA, Petersen RC, Knopman DS, *et al.* Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. *Alzheimers Dement* 2011;**7**:80–93.
- 24 Chetty R, Stepner M, Abraham S, *et al.* The association between income and life expectancy in the United States, 2001-2014. *Jama* 2016;**315**:1750–66.
- 25 Stoye G, Zaranko B, Shipley M, *et al.* Educational inequalities in hospital use among the over 65s in England. *Milbank* Q 2020.
- 26 De Nardi M, French E, Jones JB, *et al.* Medical spending of the US elderly. *Fisc Stud* 2016;**37**:717–47.
- 27 Langa KM, Ryan LH, McCammon RJ, *et al.* The health and retirement study harmonized cognitive assessment protocol project: study design and methods. *Neuroepidemiology* 2020;**54**:64–74.
- 28 Nguyen TT, Tchetgen EJT, Kawachi I, *et al.* Instrumental variable approaches to identifying the causal effect of educational attainment on dementia risk. *Ann Epidemiol* 2016;**26**:71–6.

Author Licence

I Jeremy McCauley [The Corresponding Author] of this article contained within the original manuscript which includes any diagrams & photographs within and any related or stand alone film submitted (the Contribution") has the right to grant on behalf

of all authors and does grant on behalf of all authors, a licence to the BMJ Publishing Group Ltd and its licencees, to permit this Contribution (if accepted) to be published in the BMJ and any other BMJ Group products and to exploit all subsidiary rights, as set out in our licence set out at: http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/copyright-open-access-and-permission-reuse."

IF YOU ARE A NATIONAL INSTITUTE OF HEALTH ("NIH") EMPLOYEE, CONTRACTOR OR TRAINEE the following cover sheet will be accepted by the BMJ Group and NIH and incorporated into the above Licence.

Please tick **one or more** boxes as appropriate:

- \Box I am the sole author of the Contribution.
- \checkmark I am one author signing on behalf of all co-owners of the Contribution.
- The Contribution has been made in the course of my employment and I am signing as authorised by my employer.
- I am a US Federal Government employee acting in the course of my employment.
- I am not a US Federal Government employee, but some or all of my co-authors are.
- I am an employee of the UK Crown* acting in the course of my employment
- I am a US Federal Government employee acting in the course of my employment.
- I am not a US Federal Government employee, but some or all of my co-authors are.
- I am an employee of the UK Crown acting in the course of my employment
- I am not an employee of the UK Crown acting in the course of my employment but some/all of my coauthors are.*